Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/3/2017
SIETES contiene 91704 citas

 
 
 1 a 18 de 18 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Carvalho C, Machado Caetano J, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain 2016:13 de octubre. [Ref.ID 100899]
2. Cita con resumen
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-73. [Ref.ID 99528]
3. Cita con resumen
Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, Jorgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted H-H, Villadsen AB, Aaroe J, Eggert S, Raungaard B, Kober L, DANAMI-1-PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015;386:665-71. [Ref.ID 99492]
4. Cita con resumen
Mol F, van Mello NM, Strandell A, Strandell K, Jurkovic D, Ross J, Barnhart KT, Yalcinkaya TM, Verhoeve HR, Graziosi GCM, Koks CAM, Klinte I, Hogström L, Janseen ICAH, Kragt H, Hoek A, Willemsen WNP, Ankum WM, Mol BW, van Wely M, Van der Veen F, Hajenlus PJ, for the European Surgery in Ectopic Pregnancy (ESEP) study group. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study): an open-label, multicentre, randomised controlled trial. Lancet 2014;383:1483-9. [Ref.ID 97539]
5. Cita con resumen
Sulkowski MS, Gardiner DF, Rodríguez-Torres M, Rajender Reddy K, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, for the AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21. [Ref.ID 97027]
6.Tiene citas relacionadas Cita con resumen
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, Jackisch C, de Azambuja E, Procter M, Suter TM, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne C-H, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, for the Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021-8. [Ref.ID 96181]
7.Tiene citas relacionadas
Joensuu H. Duration of adjuvant trastuzumab: shorter beats longer. Lancet 2013;382:1010-1. [Ref.ID 96180]
8. Cita con resumen
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PFA, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathioiu E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, for the COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48. [Ref.ID 94745]
9. Cita con resumen
Miselli M. Cabazitaxel. Informazioni sui Farmaci 2012;36:6-7. [Ref.ID 92778]
10. Cita con resumen
11.Tiene citas relacionadas
de Bono JS, Sartor O. Cabazitaxel for castration-resistant prostate cancer. Authors' reply. Lancet 2011;377:122-3. [Ref.ID 90045]
12.Tiene citas relacionadas
Froehner M, Wirth MP. Cabazitaxel for castration-resistant prostate cancer. Lancet 2011;377:121-2. [Ref.ID 90044]
13.Tiene citas relacionadas
Shigeta K, Miura Y, Naito Y, Takano T. Cabazitaxel for castration-resistant prostate cancer. Lancet 2011;377:121. [Ref.ID 90043]
14.Tiene citas relacionadas
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, for the TROPIC Investigators. Prednisone plus cabazitazel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54. [Ref.ID 89460]
15.
Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet 2010;376:1119-20. [Ref.ID 89459]
16.Tiene citas relacionadas
Bouadma L, Luyt C-E, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, for the PRORATA trial group. Use of procalcitonin reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74. [Ref.ID 87791]
17.Tiene citas relacionadas
Kollef MH. Will procalcitonin reduce antibiotic use in intensive care?. Lancet 2010;375:435-6. [Ref.ID 87786]
18.
Drazen JM, Morrissey S, Curfman GD. Open clinical trials. N Engl J Med 2007;357:1756-7. [Ref.ID 81335]
Seleccionar todas
 
 1 a 18 de 18